Trial Profile

A Phase 2 Umbrella Protocol of Enfortumab Vedotin as Monotherapy and Combined With Other Agents in Patients With Metastatic Castration-Resistant Prostate Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 29 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Enfortumab vedotin (Primary)
Indications Adenocarcinoma; Prostate cancer
Focus Therapeutic Use
Acronyms ENCORE

Most Recent Events

03 Jul 2024 Planned End Date changed from 1 Sep 2026 to 1 Sep 2027.
03 Jul 2024 Planned primary completion date changed from 1 Sep 2024 to 1 Sep 2025.
27 Jan 2024 Results of 11 patients in stage I presented at the 2024 Genitourinary Cancers Symposium.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com